J Korean Ophthalmol Soc > Volume 60(3); 2019 > Article
Journal of the Korean Ophthalmological Society 2019;60(3):253-260.
DOI: https://doi.org/10.3341/jkos.2019.60.3.253    Published online March 15, 2019.
Prevalence of Exudative Age-related Macular Degeneration and Projections of the Cost of Ranibizumab in Korea.
Sunyoung Ryu, Dong Wook Kim, Tyler Hyungtaek Rim, Eun Jee Chung, Jiwon Kim
1Department of Ophthalmology, National Health Insurance Service Ilsan Hospital, Goyang, Korea. plusm13@gmail.com
2Policy Research Affairs, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
3Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
습성 나이관련황반변성의 유병률 변화와 라니비주맙 주사제 사용에 따른 향후 의료비용 분석
류선영1⋅김동욱2⋅임형택3⋅정은지1⋅김지원1
국민건강보험공단 일산병원 안과1, 국민건강보험공단 일산병원 정책연구소2, 연세대학교 의과대학 안과학교실3
Correspondence:  Jiwon Kim,
Email: plusm13@gmail.com
Received: 21 June 2018   • Revised: 16 September 2018   • Accepted: 19 February 2019
Abstract
PURPOSE
To analyze the incidence and prevalence of exudative age-related macular degeneration (AMD) and to predict the future AMD populations and health expenditures of intravitreal ranibizumab injection. METHODS: From 2010 to 2014, the National Health Insurance claims data were used to estimate the incidence and prevalence change of exudative AMD, according to demographic characteristics (year, sex, residence, and age). Based on the above results and changes in future population distribution, we estimated the AMD population by 2030. Considering the cost of Intravitreal ranibizumab injection from 2010 to 2014, we predicted the future health expenditure for AMD. RESULTS: The incidence and prevalence of exudative AMD increased from 14.04 and 295.11 per 100,000 populations in 2010 to 14.25 and 580.71 in 2014, respectively. The prevalence rate was higher in men and showed a large increase over 70 years of age. The ranibizumab was prescribed 13 times per person in average, and the amount consumed increased as the number of insurance coverage increased from 2013. Future AMD populations are predicted to reach 557,007 in 2030 from 146,871 in 2014. As a result, the cost of intravitreal ranibizumab injection is expected to increase from 83.6 billion won in 2014 to 171.7 billion won in 2030. CONCLUSIONS: The increase in medical expenses for AMD is expected due to social aging. Therefore, we need policies to secure medical resources and expand insurance indications.
Key Words: Age-related macular degeneration;Health expenditure;Prevalence;Ranibizumab


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next